*SAGIMET BIOSCIENCES ANNOUNCES CLEARANCE OF IND FOR FASN INHIBITOR TVB-3567, TO BE DEVELOPED FOR THE TREATMENT OF ACNE
*SAGIMET BIOSCIENCES INC - FIRST-IN-HUMAN PHASE 1 TRIAL OF TVB-3567 PLANNED IN 2025
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 11-MAR-202512:00:03.297 GMT